FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

November 17, 2022 by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs
(Photo by Anna Dudkova via UnSplash)

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs. 

Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.  

Pancreatitis is a painful inflammatory disease of the pancreas that can be life-threatening and generally requires that dogs be hospitalized for treatment. In most cases, it occurs spontaneously. 

Common factors that increase the chance of developing pancreatitis include when dogs eat something outside of their normal diet (particularly fatty foods), treatment with certain medications, and diseases like diabetes mellitus, the FDA said.

It is more common in certain breeds of dogs and in some dogs may become a recurring or chronic condition. 

“This is the first drug to address a serious and life-threatening disease that previously could only be managed through supportive care, such as intravenous fluids, pain medication, antiemetics, and dietary rest,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine, in a written statement. 

“The conditional approval pathway allows medications like Panoquell-CA1 to reach the marketplace more quickly, and in this case gives dogs suffering from acute onset of pancreatitis earlier access to a drug to manage this disease,”  he said.

Conditional approval means that, when used according to the label, the drug is safe and has a reasonable expectation of effectiveness. 

The initial conditional approval is valid for one year with the potential for four annual renewals. 

During this time, the animal drug sponsor – in this case Ishihara Sangyo Kaisha Ltd. – must demonstrate active progress toward proving substantial evidence of effectiveness for full approval. 

If the sponsor does not meet the requirements for substantial evidence of effectiveness at the conclusion of five years, the product can no longer be marketed.

Fuzapladib sodium, the active ingredient in Panoquell, has been approved since 2018 in Japan to improve clinical signs in the acute phase of pancreatitis in dogs, but not in the United States until Tuesday. 

The FDA reviewed data associated with fuzapladib’s use in Japan as part of its assessment of the application for conditional approval. 

The agency said veterinarians should advise owners about the possible side effects, which include loss of appetite, digestive tract disorders, respiratory tract disorders, liver disease and jaundice, before using the drug. 

It is also encouraging dog owners to work with their veterinarian to report any adverse events or side effects potentially related to the use of any drug, including Panoquell-CA1. 

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • dogs
  • FDA
  • Pancreatitis
  • Panoquell-CA1
  • In The News

    Health

    Voting

    Regulation

    Decision Looming for Trump Administration on First PFAS Drinking Water Limits

    In pain so bad he couldn’t stand, Chris Meek was rushed to the hospital with a life-threatening ruptured gallbladder. When... Read More

    In pain so bad he couldn’t stand, Chris Meek was rushed to the hospital with a life-threatening ruptured gallbladder. When he emerged from surgery, he learned he had kidney cancer that thankfully hadn’t yet spread. Meek, a social studies teacher in Wilmington, North Carolina, was 47... Read More

    Election Officials From Across the US Meet to Consider Trump's Order Overhauling Election Operations

    CHARLOTTE, N.C. (AP) — State and local election officials from across the country are meeting Thursday to consider President Donald... Read More

    CHARLOTTE, N.C. (AP) — State and local election officials from across the country are meeting Thursday to consider President Donald Trump’s executive order that seeks major changes to how elections are run, the first time those in charge of the nation's voting will formally gather to weigh in... Read More

    April 22, 2025
    by Tom Ramstack
    Federal Trade Commission Sues Uber Alleging Deceit in Subscriptions

    SAN FRANCISCO — The Federal Trade Commission sued rideshare company Uber Technologies Inc. Monday, alleging a pattern of deceit against... Read More

    SAN FRANCISCO — The Federal Trade Commission sued rideshare company Uber Technologies Inc. Monday, alleging a pattern of deceit against consumers intended to maximize profits. The lawsuit says Uber used hidden charges, failed to deliver on promised savings and made it difficult for customers to cancel... Read More

    April 15, 2025
    by Tom Ramstack
    Meta’s Zuckerberg Defends Against Allegations of Monopoly Tactics

    WASHINGTON — Meta Platforms Chief Executive Mark Zuckerberg testified for a second day Tuesday in a Washington, D.C., court that... Read More

    WASHINGTON — Meta Platforms Chief Executive Mark Zuckerberg testified for a second day Tuesday in a Washington, D.C., court that his company has encouraged the growth of social media but not the anticompetitive dominance alleged by the Federal Trade Commission. The trial in the antitrust case... Read More

    March 28, 2025
    by Dan McCue
    FCC Opens Probe Into DEI Practices at Disney, ABC

    WASHINGTON — Federal Communications Commission Chair Brendan Carr on Friday directed the agency’s Enforcement Bureau to open an investigation into... Read More

    WASHINGTON — Federal Communications Commission Chair Brendan Carr on Friday directed the agency’s Enforcement Bureau to open an investigation into the DEI practices of The Walt Disney Company and its flagship television network, ABC. “While Disney started as an iconic American company, it recently went all... Read More

    March 14, 2025
    by Dan McCue
    FCC Asks Public: ‘What Rules Do You Want Us to Toss?’

    WASHINGTON — “In re: Delete, Delete, Delete.” That’s the name of a new docket created by the Federal Communications Commission... Read More

    WASHINGTON — “In re: Delete, Delete, Delete.” That’s the name of a new docket created by the Federal Communications Commission through which it is soliciting comments on “every rule, regulation or guidance” the general public and the communications industry wants to see eliminated. “The FCC has... Read More

    News From The Well
    scroll top